These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. Nazzani S; Preisser F; Mazzone E; Tian Z; Mistretta FA; Shariat SF; Soulières D; Saad F; Montanari E; Luzzago S; Briganti A; Carmignani L; Karakiewicz PI World J Urol; 2019 Jul; 37(7):1329-1337. PubMed ID: 30298285 [TBL] [Abstract][Full Text] [Related]
4. Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. Nazzani S; Mazzone E; Preisser F; Tian Z; Mistretta FA; Shariat SF; Montanari E; Acquati P; Briganti A; Saad F; Carmignani L; Karakiewicz PI Eur J Surg Oncol; 2019 Jul; 45(7):1238-1245. PubMed ID: 30563773 [TBL] [Abstract][Full Text] [Related]
5. Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients. Morra S; Incesu RB; Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Creta M; Califano G; Collà Ruvolo C; Saad F; Shariat SF; Chun FKH; de Cobelli O; Musi G; Briganti A; Tilki D; Ahyai S; Carmignani L; Longo N; Karakiewicz PI World J Urol; 2024 May; 42(1):343. PubMed ID: 38775841 [TBL] [Abstract][Full Text] [Related]
6. Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy. Zhai TS; Jin L; Zhou Z; Liu X; Liu H; Chen W; Lu JY; Yao XD; Feng LM; Ye L BMC Cancer; 2019 Dec; 19(1):1207. PubMed ID: 31830927 [TBL] [Abstract][Full Text] [Related]
7. Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. Nazzani S; Preisser F; Mazzone E; Tian Z; Mistretta FA; Soulières D; Montanari E; Acquati P; Briganti A; Shariat SF; Abdollah F; Carmignani L; Karakiewicz PI Eur Urol Focus; 2020 Mar; 6(2):298-304. PubMed ID: 30266210 [TBL] [Abstract][Full Text] [Related]
8. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Lughezzani G; Jeldres C; Isbarn H; Sun M; Shariat SF; Alasker A; Pharand D; Widmer H; Arjane P; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI Eur J Cancer; 2009 Dec; 45(18):3291-7. PubMed ID: 19615885 [TBL] [Abstract][Full Text] [Related]
9. Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study. Kang HW; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YD; Ha YS; Kim TH; Kwon TG; Byun SS; Jeh SU; Kim WJ J Korean Med Sci; 2017 Feb; 32(2):335-342. PubMed ID: 28049247 [TBL] [Abstract][Full Text] [Related]
10. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. Lughezzani G; Sun M; Perrotte P; Shariat SF; Jeldres C; Budäus L; Latour M; Widmer H; Duclos A; Bénard F; McCormack M; Montorsi F; Karakiewicz PI Urology; 2010 Feb; 75(2):321-7. PubMed ID: 19962727 [TBL] [Abstract][Full Text] [Related]
15. The effectiveness of chemotherapy for patients with pT3N0M0 renal pelvic urothelial carcinomas: An inverse probability of treatment weighting comparison using Surveillance, Epidemiology, and End Results data. Liu Z; Huang J; Li X; Huang C; Ye Y; Zhang J; Liu Z Cancer Med; 2020 Aug; 9(16):5756-5766. PubMed ID: 32585775 [TBL] [Abstract][Full Text] [Related]
16. Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study. Fujita K; Inamoto T; Yamamoto Y; Tanigawa G; Nakayama M; Mori N; Tsujihata M; Azuma H; Nonomura N; Uemura M Int J Urol; 2015 Nov; 22(11):1006-12. PubMed ID: 26153093 [TBL] [Abstract][Full Text] [Related]
17. Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma. Lin WY; Lin MH; Yang YH; Chen WC; Huang CE; Chen MF; Wu CT Front Surg; 2022; 9():903123. PubMed ID: 35693310 [TBL] [Abstract][Full Text] [Related]
18. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy. Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922 [TBL] [Abstract][Full Text] [Related]
19. Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012). Chappidi MR; Kates M; Johnson MH; Hahn NM; Bivalacqua TJ; Pierorazio PM Urol Oncol; 2016 Dec; 34(12):531.e15-531.e24. PubMed ID: 27476032 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]